- All
- Product Name
- Product Keyword
- Product Model
- Product Summary
- Product Description
- Multi Field Search
Views: 54 Author: Unibest Industrial Publish Time: 2024-07-29 Origin: Site
Query Drug：DEUCRAVACITINIB
Query Time：2024-07-24 16:36:49
*** Disclaimer *** The information provided here is sourced from resources such as Drugs.com, the Orange Book, etc., and is auto-generated by the Unibest Digital Center. The content is intended exclusively for pharmaceutical professionals. Unibest does NOT accept legal responsibility for ANY medical actions taken based on this information. ALWAYS consult with your doctor for medical advice. In addition, this product uses publicly available data from the U.S. National Library of Medicine (NLM), National Institutes of Health, Department of Health and Human Services; NLM is not responsible for the product and does not endorse or recommend this or any other product.
Deucravacitinib (brand name Sotyktu) is a once-daily, oral tyrosine kinase 2 (TYK2) blocker that may be used to treat adults with moderate to severe plaque psoriasis who are candidates for systemic therapy or phototherapy (light therapy).
Deucravacitinib works by blocking an immune system protein called TYK2 which has a role in inflammation and has been associated with plaque psoriasis. Blocking TYK2 improves psoriasis symptoms and reduces the severity and number of psoriasis lesions.
Deucravacitinib was FDA approved on September 9, 2022, under the brand name Sotyktu. There is no Sotyktu generic available.
Parapsoriasis
Source MEDRT
Source MEDRT
Source: MEDRT
Source MEDRT
Source FDASPL
Source DAILYMED
Source FDASPL
Source DAILYMED
[Last update] 2024-07-08
DEUCRAVACITINIB's Innovator is BRISTOL MYERS SQUIBB CO
The unique dosage forms from the innovator include：1. TABLET;ORAL.
| Index | Route | Brand Name | Labeler | Approval Date | Dosage |
|---|---|---|---|---|---|
| 1 | TABLET;ORAL | SOTYKTU | BRISTOL MYERS SQUIBB CO | Sep 9, 2022 | 6MG |
This drug still has 3 effective patents.
| Patent Number | Submission Date | Expiration Date | Drug Substance Patent? | Drug Product Patent? |
|---|---|---|---|---|
| RE47929 | Oct 4, 2022 | Nov 7, 2033 | Y | Y |
| 11021475 | Oct 4, 2022 | Nov 7, 2033 | ||
| 10000480 | Oct 4, 2022 | Nov 7, 2033 | Y | Y |
The innovator BRISTOL MYERS SQUIBB CO's portolio contains products with the following 34 API(s)： STAVUDINE, AMITRIPTYLINE HYDROCHLORIDE, TRIFLUPROMAZINE HYDROCHLORIDE, ATAZANAVIR SULFATE; COBICISTAT, TRISULFAPYRIMIDINES (SULFADIAZINE;SULFAMERAZINE;SULFAMETHAZINE), TESTOLACTONE, RESERPINE, OZANIMOD HYDROCHLORIDE, ESTRADIOL, GLIPIZIDE; METFORMIN HYDROCHLORIDE, NEOMYCIN SULFATE, AMINOSALICYLIC ACID RESIN COMPLEX, ATAZANAVIR SULFATE, TUBOCURARINE CHLORIDE, REPOTRECTINIB, DASATINIB, DEUCRAVACITINIB, ASPIRIN; PRAVASTATIN SODIUM, CEPHRADINE, DIDANOSINE, POMALIDOMIDE, EFAVIRENZ, DOXORUBICIN HYDROCHLORIDE, VITAMIN A PALMITATE, ESTROGENS, ESTERIFIED, AZACITIDINE, ERYTHROMYCIN STEARATE, AMPHOTERICIN B, AMPICILLIN/AMPICILLIN TRIHYDRATE, AZTREONAM, CYANOCOBALAMIN, ISONIAZID, FLUPHENAZINE DECANOATE, MAVACAMTEN
The above products are related to 135 diseases： Acquired Immunodeficiency Syndrome, Depressive Disorder, Pain, Nausea, Hiccup, Vomiting, Pain, Psychotic Disorders, Acquired Immunodeficiency Syndrome, HIV Infections, Breast Neoplasms, Schizophrenia, Dyskinesias, Hypertension, Multiple Sclerosis, Relapsing-Remitting, Breast Neoplasms, Hot Flashes, Primary Ovarian Insufficiency, Hypogonadism, Menopause, Premature, Menorrhagia, Prostatic Neoplasms, Osteoporosis, Postmenopausal, Diabetes Mellitus, Type 2, Diabetes Mellitus, Type 2, Bacterial Infections, Escherichia coli Infections, Skin Diseases, Bacterial, Hepatic Encephalopathy, Acquired Immunodeficiency Syndrome, Myasthenia Gravis, Leukemia, Myeloid, Leukemia, Lymphoid, Parapsoriasis, Ischemic Attack, Transient, Myocardial Infarction, Cerebral Infarction, Osteoarthritis, Arthritis, Rheumatoid, Gout, Pain, Fever, Pre-Eclampsia, Inflammation, Rheumatic Fever, Hyperlipoproteinemias, Hypertriglyceridemia, Coronary Artery Disease, Hypercholesterolemia, Soft Tissue Infections, Respiratory Tract Infections, Skin Diseases, Bacterial, Escherichia coli Infections, Streptococcal Infections, Urinary Tract Infections, Klebsiella Infections, Proteus Infections, Staphylococcal Infections, Acquired Immunodeficiency Syndrome, Multiple Myeloma, Acquired Immunodeficiency Syndrome, Neuroblastoma, Precursor Cell Lymphoblastic Leukemia-Lymphoma, Wilms Tumor, Gastrointestinal Neoplasms, Prostatic Neoplasms, Breast Neoplasms, Ovarian Neoplasms, Multiple Myeloma, Leukemia, Myeloid, Acute, Lung Neoplasms, Pancreatic Neoplasms, Urinary Bladder Neoplasms, Osteosarcoma, Uterine Neoplasms, Soft Tissue Neoplasms, Mesothelioma, Liver Neoplasms, Testicular Neoplasms, Thyroid Neoplasms, Hodgkin Disease, Night Blindness, Xerophthalmia, Vitamin A Deficiency, Photosensitivity Disorders, Dermatitis, Malabsorption Syndromes, Anemia, Sideroblastic, Leukemia, Myelomonocytic, Chronic, Anemia, Refractory, Eye Infections, Bacterial, Erythrasma, Legionnaires' Disease, Syphilis, Urethritis, Campylobacter Infections, Gonorrhea, Streptococcal Infections, Chancroid, Chlamydia Infections, Whooping Cough, Acne Vulgaris, Gastroenteritis, Staphylococcal Infections, Mycoplasma Infections, Mycoses, Urinary Tract Infections, Sporotrichosis, Neutropenia, Leishmaniasis, Visceral, Cystitis, Candidiasis, Cutaneous, Candidiasis, Zygomycosis, Candidiasis, Chronic Mucocutaneous, Aspergillosis, Fungemia, AIDS-Related Opportunistic Infections, Blastomycosis, Paracoccidioidomycosis, Meningitis, Cryptococcal, Coccidioidomycosis, Histoplasmosis, Peritonitis, Cellulitis, Respiratory Tract Infections, Endometritis, Pseudomonas Infections, Intraabdominal Infections, Urinary Tract Infections, Sepsis, Tuberculosis, Schizophrenia, Psychotic Disorders, Cardiomyopathy, Hypertrophic
